VIVARUS
Diagnostics
Rare Disease Intelligence at the Point of Care
We are building a clinical decision support system that reads the hospital record a patient already has and surfaces the rare diagnoses that fit it — each one shown against the published criteria it matches, the evidence that supports it, and the evidence that argues against it.
The delay is not in the patient. Its in the system.
In the largest European survey of its kind, patients waited an average of 4.7 years from first symptom to confirmed diagnosis. Roughly nine tenths of that time passed after they had already sought medical help. Seventy-three per cent were diagnosed with a different disease at least once along the way.
That gap is not a failure of clinical skill. A hospital haematologist may see a given ultra-rare condition once in a career, and rare presentations arrive disguised as common ones. But by the time the diagnosis is finally made, the evidence for it is usually already in the record — scattered across years of laboratory results, notes, referrals and discharge summaries, and never assembled into a single view.
That assembly is the problem we work on.
Vivarus Diagnostics grew out of years spent working in rare disease therapy development, where we saw a recurring pattern: patients waiting far too long for answers. Despite the dedication of clinicians, the sheer complexity and rarity of these conditions often makes early recognition incredibly difficult. With backgrounds in biochemistry, medicine, and pharma, we started Vivarus Diagnostics to build tools that can quietly support clinicians behind the scenes — making rare feel a little more recognizable.
300M+
people worldwide live with a rare disease — between 3.5% and 5.9% of the population
4.7 years
average time from first symptom to confirmed diagnosis across 41 European countries
~90%
of that delay falls after the first medical contact, not before it
7.6x
higher direct healthcare costs before diagnosis than matched controls, in German claims data
Sources, in order: Nguengang Wakap et al., European Journal of Human Genetics (2020) · EURORDIS Rare Barometer, European Journal of Human Genetics (2024), n=6,507 · same · Orphanet Journal of Rare Diseases (2025), n=1,243.
Mission & Vision
Our mission is to accelerate the diagnosis of rare diseases by equipping clinicians with AI-powered tools that support earlier recognition and smarter decision-making — without adding complexity to their workflow.
We envision a world where no patient waits years for a diagnosis simply because their condition is rare. By bridging biomedical science with intelligent technology, we aim to make rare disease diagnosis faster, more accurate, and accessible across all levels of care.
Our Values
Patient focus
Behind every diagnosis is a person shaped by uncertainty. We build with empathy to honor their experiences and support those who care for them.
Collaboration
Solving complex problems takes more than code — it takes people. We work closely with clinicians and researchers to create tools that truly fit into real-world care.
Patient-Centered Innovation
Innovation means nothing if it doesn’t reach the right people. We design technology that is intuitive, clinically meaningful, and built to improve lives.
Looking Ahead
Our current focus is on high-impact rare diseases where early diagnosis can significantly change outcomes. As we grow, we aim to expand our database, deepen our algorithms, and integrate seamlessly across care settings — from primary care to specialist centers.
Built for the Front Line
Vivarus Diagnostics is designed with and for clinicians. We collaborate closely with doctors, data scientists, and healthcare systems to ensure our tool is clinically relevant, technically robust, and easy to use. Because in real-world care, simplicity and trust matter as much as accuracy.
Our unique approach
Our proprietary system operates quietly in the background of a clinician’s workflow, using structured and unstructured patient data to detect rare disease signals. It’s designed to:
-
Recognize subtle diagnostic patterns across symptoms, labs, history, and more
-
Surface possible rare diseases that match the profile — even if they’re not top-of-mind
-
Provide explainable insights, so clinicians understand why a suggestion was made
-
Integrate with existing systems to minimize friction and support adoption
The goal is not to replace clinical judgment — it’s to give healthcare professionals an extra layer of insight when it’s needed most.
Our Solution
Making Rare Diagnoses Less Rare
Vivarus Diagnostics is developing an AI-powered decision support tool designed to help clinicians identify rare diseases earlier and with greater confidence. Our technology integrates biomedical data and clinical patterns to highlight possible diagnoses that may otherwise be overlooked in day-to-day practice.
Why This Matters
Diagnosing rare diseases is incredibly difficult — not because clinicians aren’t skilled, but because these conditions are, by nature, uncommon and complex. Many present with vague, overlapping symptoms, leading to diagnostic delays that can stretch across years. By supporting clinicians with intelligent, pattern-based suggestions, Vivarus Diagnostics helps bring rare diseases into view sooner.
Built into your workflow
Vivarus Dx integrates into hospital workflows and reads existing records automatically. It does not replace the clinician — it makes rare patterns visible, explains its reasoning, and guides the doctor in this critical, time-sensitive moment.
Reads records, finds rare patterns — ingests structured and unstructured hospital data; no manual data entry required.
Guideline-matched evidence — every suggestion is traced to published clinical criteria and citations, not a black-box score.
Transparent confidence per condition — ranked differential with supporting evidence, contradictions, and high-yield next tests.
Enterprise-ready from day one — secure, auditable, EU-hosted, with a defined MDR medical-device certification path.
CRO / trial screening layer — pre-screens site records to surface eligible candidates, cutting screen-fail rates from ~70% to ~50%.
News
